Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Freenome"

2 News Found

Freenome strikes SPAC deal to go public in 2026
Biotech | December 08, 2025

Freenome strikes SPAC deal to go public in 2026

Freenome expects the combined company to receive approximately $330 million in proceeds at closing

Freenome acquires global immunodiagnostics developer Oncimmune
News | May 23, 2023

Freenome acquires global immunodiagnostics developer Oncimmune

Acquisition enhances Freenome's product portfolio, including autoantibody platform with additional biomarkers important in cancer detection

Latest Stories

Lupin receives positive CHMP opinion for biosimilar Ranibizumab

Biocon Biologics honored as 2025 Asia IP Elite by IAM for 9th consecutive year

AstraZeneca India receives permission from CDSCO for Datopotamab Deruxtecan powder

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories

Packaging